Company news
Bluenergies Ltd. news in 2017
Bluenergies Ltd.'s news releases, calls and decks from 2017, newest first.
BELLUS Health Closes $20M Common Share Financing
December 12, 2017
BELLUS Health Announces Pricing of up to $20M Equity Offering
December 5, 2017
BELLUS Health Announces Overnight Marketed Equity Offering
December 4, 2017
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017
November 8, 2017
BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors
September 27, 2017
BELLUS Health Chronic Cough Webcast Taking Place Today
September 20, 2017
BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models
September 18, 2017
BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017
September 6, 2017
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017
August 9, 2017
BELLUS Health announces closing of the sale of its equity interest in FB Health for total consideration up to CA$2.5M
July 3, 2017
BELLUS Health announces sale of its equity interest in FB Health for total consideration up to CA$2.5M
June 19, 2017
BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2017
May 9, 2017
BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
April 27, 2017
BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
April 24, 2017
BELLUS Health Announces the Sale of Subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals
March 16, 2017
Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016
February 28, 2017
BELLUS Health and The NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough
February 28, 2017
Bellus Health Announces Payment to Thallion CVR Holders
February 17, 2017